AVEO to provide tivozanib preclinical data.

today announced that preclinical data on tivozanib, AVEO’s lead product candidate made to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and the company’s monoclonal antibody pipeline will be presented during poster classes at the American Association for Cancers Analysis 102nd Annual Meeting 2011 being kept April 2-6, 2011 in Orlando, Fla. We look forward to sharing these preclinical data on our business lead product applicant tivozanib and our deep pipeline of monoclonal antibodies with our peers in the oncology research community, stated William Slichenmyer, M.D., Sc.M., chief medical officer at AVEO. .. AVEO to provide tivozanib preclinical data, monoclonal antibody pipeline at AACR meeting AVEO Pharmaceuticals, Inc.A complete of 17 skin attacks occurred among the 80 patients in the placebo organizations , as compared with 6 epidermis infections among the 127 dupilumab-treated patients , corresponding to a rate of skin infection in the placebo group that was 4 times as high as the rate in the dupilumab group . In the 12-week monotherapy study, 14 skin infections occurred in the placebo group, as compared with 4 in the dupilumab group. Among the patients in the placebo group, 7 needed hospitalization , in comparison with 1 in the dupilumab group .